NAVA Relative Valuation - Navamedic ASA

Watchlist Manager

Watchlist

Price: 21.6 NOK 0.93% Market Closed

Market Cap: kr518m

Relative Value

The Relative Value of one NAVA stock under the Base Case scenario is hidden NOK. Compared to the current market price of 21.6 NOK, Navamedic ASA is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

What is Relative Valuation?

How is Relative Value calculated?

NAVA Relative Value

Show

Worst Case

Base Case

Best Case

Valuation Multiples

View Details

Multiples Across Competitors

All Multiples

P/S

P/E

EV/EBITDA

EV/EBIT

Forward Multiples

			Market Cap	P/S	P/E	EV/EBITDA	EV/EBIT
NO	N	Navamedic ASA OSE:NAVA	518m NOK	1	-13.1	91.6	91.6
US		Eli Lilly and Co NYSE:LLY	987.9B USD	15.2	47.9	32.3	34.3
US		Johnson & Johnson NYSE:JNJ	596.5B USD	6.3	22.3	15.4	19
CH		Roche Holding AG SIX:ROG	293B CHF	4.8	31.2	13.1	15.3
CH		Novartis AG SIX:NOVN	249.7B CHF	5.7	23	14.2	18.2
UK		AstraZeneca PLC LSE:AZN	240.5B GBP	5.5	31.7	17.5	24.7
US		Merck & Co Inc NYSE:MRK	307.4B USD	4.7	16.8	10.5	12.3
IE	E	Endo International PLC LSE:0Y5F	218B USD	94	-74.6	344.9	865
DK		Novo Nordisk A/S CSE:NOVO B	1.1T DKK	3.4	10.4	7.7	9
US		Pfizer Inc NYSE:PFE	156.9B USD	2.5	20.2	7.5	10
US		Bristol-Myers Squibb Co NYSE:BMY	125.6B USD	2.6	17.8	7.4	9.2

				Revenue Growth	P/S to Growth
NO	N	Navamedic ASA OSE:NAVA	Average P/S: 13.2 1	17%	0.1
US		Eli Lilly and Co NYSE:LLY	15.2	19%	0.8
US		Johnson & Johnson NYSE:JNJ	6.3	6%	1.1
CH		Roche Holding AG SIX:ROG	4.8	3%	1.6
CH		Novartis AG SIX:NOVN	5.7	5%	1.1
UK		AstraZeneca PLC LSE:AZN	5.5	7%	0.8
US		Merck & Co Inc NYSE:MRK	4.7	5%	0.9
IE	E	Endo International PLC LSE:0Y5F	94	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	3.4	3%	1.1
US		Pfizer Inc NYSE:PFE	2.5	-4%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	2.6	-5%	N/A

				Earnings Growth	PEG
NO	N	Navamedic ASA OSE:NAVA	Average P/E: 24.6 Negative Multiple: -13.1	N/A	N/A
US		Eli Lilly and Co NYSE:LLY	47.9	28%	1.7
US		Johnson & Johnson NYSE:JNJ	22.3	7%	3.2
CH		Roche Holding AG SIX:ROG	31.2	29%	1.1
CH		Novartis AG SIX:NOVN	23	15%	1.5
UK		AstraZeneca PLC LSE:AZN	31.7	26%	1.2
US		Merck & Co Inc NYSE:MRK	16.8	14%	1.2
IE	E	Endo International PLC LSE:0Y5F	Negative Multiple: -74.6	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	10.4	7%	1.5
US		Pfizer Inc NYSE:PFE	20.2	26%	0.8
US		Bristol-Myers Squibb Co NYSE:BMY	17.8	17%	1

				EBITDA Growth	EV/EBITDA to Growth
NO	N	Navamedic ASA OSE:NAVA	Average EV/EBITDA: 51.1 91.6	17%	5.4
US		Eli Lilly and Co NYSE:LLY	32.3	22%	1.5
US		Johnson & Johnson NYSE:JNJ	15.4	2%	7.7
CH		Roche Holding AG SIX:ROG	13.1	5%	2.6
CH		Novartis AG SIX:NOVN	14.2	5%	2.8
UK		AstraZeneca PLC LSE:AZN	17.5	13%	1.3
US		Merck & Co Inc NYSE:MRK	10.5	5%	2.1
IE	E	Endo International PLC LSE:0Y5F	344.9	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	7.7	2%	3.8
US		Pfizer Inc NYSE:PFE	7.5	-9%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	7.4	-10%	N/A

				EBIT Growth	EV/EBIT to Growth
NO	N	Navamedic ASA OSE:NAVA	Average EV/EBIT: 100.8 91.6	30%	3.1
US		Eli Lilly and Co NYSE:LLY	34.3	22%	1.6
US		Johnson & Johnson NYSE:JNJ	19	7%	2.7
CH		Roche Holding AG SIX:ROG	15.3	6%	2.6
CH		Novartis AG SIX:NOVN	18.2	9%	2
UK		AstraZeneca PLC LSE:AZN	24.7	21%	1.2
US		Merck & Co Inc NYSE:MRK	12.3	6%	2
IE	E	Endo International PLC LSE:0Y5F	865	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	9	3%	3
US		Pfizer Inc NYSE:PFE	10	-4%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	9.2	-7%	N/A

Navamedic ASA
OSE:NAVA

Relative Value

Valuation Multiples

Multiples Across Competitors

NAVA Competitors Multiples
Navamedic ASA Competitors

See Also

Company

Help

Tools

Stocks

Navamedic ASA OSE:NAVA

Relative Value

Valuation Multiples

Multiples Across Competitors

NAVA Competitors Multiples Navamedic ASA Competitors

See Also

Company

Help

Tools

Stocks

Navamedic ASA
OSE:NAVA

NAVA Competitors Multiples
Navamedic ASA Competitors